Zolgensma Fall-Out: Is Threat To Novartis – Or US FDA Climate Overall?
Executive Summary
FDA’s disclosure of data “manipulation” in the application for the SMA gene therapy Zolgensma prompted two immediate inquiries from the US Senate – with very different focuses and potential outcomes.